+86-28-82633987
Synonym name: Techtochrysin; Techtochrysine; Tectochrysin
Catalogue No.: BP0103
Cas No.: 520-28-5
Formula: C16H12O4
Mol Weight: 268.268
Botanical Source: Alpinia oxyphylla Miq.
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.
For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.
Description:
Tectochrysin is a promising inhibitor for the reversal of ABCG2-mediated drug transport, it leads to apoptotic cell death in NSCLC cells through activation of DR3 and Fas expression via inhibition of STAT3 phosphorylation.Tectochrysin has antioxidant effect, it also exhibits a significant hepatoprotective activity in hepatic damage induced by CCl4-intoxication in rats.
References:
Arch Pharm Res. 2003 Jan;26(1):43-6.
In vivo anti-oxidant activities of tectochrysin.
The anti-oxidant activities of Tectochrysin, a major compound of propolis, were investigated.
METHODS AND RESULTS:
Tectochrysin exhibited a significant decrease in serum transaminase activities elevated by hepatic damage induced by CCl4-intoxication in rats. Tectochrysin tested exhibited a lipid peroxidation causing a significant decrease in MDA production in TBA-reactant assay. Tectochrysin was strong in the increase in the anti-oxidant enzymes such as hepatic cytosolic superoxide dismutase, catalase and glutathione peroxidase activities in CCl4-intoxicated rats.
CONCLUSIONS:
These results suggest that Tectochrysin possess not only the anti-oxidant, but also the activities in CCl4-intoxicated rats. Especially, Tectochrysin was found to cause significant increases in the rat liver cytosolic SOD, catalase, GSH-px activities as well as a significant decrease in the MDA production.
HPLC of Techtochrysin
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
63.6000
3.0400
2.8000
Low
No
No
No
No
No
No
No
Flavonoids, as plant secondary metabolites, have long attracted attention in pharmacology and natural product chemistry due to their broad biological activity and potential medicinal value. Techtochrysin (CAS No.: 520-28-5) is a monohydroxymonomethoxyflavonoid containing hydroxyl groups at position 4 and methoxy group at position 7 in the flavonoid backbone. Due to its unique chemical properties and diverse biological activities, it has become a research hotspot in recent years. Yangsha Huangxin not only exhibits significant antitumor activity, but also has functions of stopping diarrhea and regulating plant metabolism, demonstrating its potential application value in the treatment of various diseases.
Especially in cardiovascular diseases, myoxanthin shows regulatory effects on multiple targets related to myocardial infarction (MI), such as APP, PTPN1, MAOA, ABCB1, and ABCG2, suggesting that it may exert myocardial protection through multi-target synergistic effects. In addition, the druggability parameters of yangyasha flavin are good, with low hepatotoxicity, no cardiotoxicity, and hERG channel inhibition, providing a solid safety foundation. This paper aims to systematically review the chemical structure, plant origin, pharmacological activity, mechanism of action, druggability evaluation, and clinical application prospects of bayberry lutein, aiming to provide a theoretical basis and reference for future drug development and clinical research.
Yangsha Xanthin is a monohydroxymonomethoxyflavone among flavonoids, with the chemical formula C_16H_12O_5 and a molecular weight of 284.26. Its structural feature is the substitution of 4 hydroxyl (-OH) and 7 methoxy (-OCH_3) groups in the flavonoid backbone, endowing it with unique physicochemical properties and biological activity. The LogP value of singing lutein is 3.04, indicating moderate hydrophobicity, which is beneficial for cell membrane penetration and bioavailability. Its polar surface area (TPSA) is 63.6 Ų, and it has 4 hydrogen bond receptors, suggesting certain hydrophilicity and binding potential in intermolecular interactions.
From a molecular conformational perspective, the 4-position hydroxyl group provides hydrogen bond donor function, while the presence of the 7-position methoxy group enhances the molecule's hydrophobicity and stability. This structural combination allows yangshaxanthin to form stable hydrogen bonds when binding to protein targets and to enhance affinity through hydrophobicity. Additionally, myoxanthin exhibits low blood-brain barrier penetration ability, suggesting limited activity in the central nervous system, but also reducing the risk of potential CNS toxicity.
Yangya Xanthin is mainly found in various Chinese medicinal materials and plants, especially certain flavonoid-rich plants such as Yangya genus. Its naturally occurring form is mostly in free or bound form, with its content greatly affected by plant species, growth environment, and harvest time. Common plant sources include species named Techtochrysin and related genera, as well as other medicinal plants rich in flavonoids.
The extraction method mostly uses organic solvent extraction combined with chromatography separation technology. Common extraction solvents include ethanol, methanol, and their aqueous solutions. The extraction process is usually carried out at medium to low temperatures to avoid degradation of heat-sensitive components. After extraction, yangbrolutein was purified using silica gel column chromatography, reversed-phase high-performance liquid chromatography (RP-HPLC), and other methods. In recent years, ultrasound-assisted extraction and microwave-assisted extraction technologies have been introduced to improve extraction efficiency and purity, while reducing solvent usage and extraction time.
After purification, yangshaxanthin is identified through mass spectrometry (MS), nuclear magnetic resonance (NMR), and infrared spectroscopy (IR), ensuring its purity and structural accuracy, providing a reliable material basis for subsequent pharmacological activity studies.
The pharmacological activities of myrtle flavin cover multiple aspects including anti-tumor, antidiarrheal, anti-inflammatory, and cardiovascular protection, demonstrating its potential as a versatile natural product.
Numerous in vitro cell experiments and some in vivo model studies have shown that myoxanthin inhibits proliferation, induces apoptosis, and blocks the cell cycle in various tumor cells. Its mechanism involves regulating tumor-related signaling pathways such as PI3K/Akt, MAPK, and NF-κB pathways, thereby affecting cell proliferation, migration, and invasion capabilities. Additionally, yangsha flavin can regulate the tumor microenvironment, inhibit tumor angiogenesis, and enhance the sensitivity of chemotherapy drugs, demonstrating potential adjuvant therapeutic value.
As a traditional antidiarrheal ingredient, yangsha flavin works by regulating the contractility and secretion of intestinal smooth muscle, thereby achieving antidiarrheal effects. Its mechanism of action may be related to inhibiting the release of intestinal inflammatory factors, regulating gut microbiota balance, and enhancing intestinal barrier function. Animal experiments have shown that yangbroxlavin can effectively reduce diarrhea symptoms and shorten the course of illness.
In models of myocardial infarction and related cardiovascular diseases, myoxanthin exhibits antioxidant, anti-inflammatory, and anti-apoptotic effects. It can regulate oxidative stress levels within myocardial cells, inhibit the release of inflammatory mediators, and protect myocardial cells from ischemia-reperfusion injury. Additionally, myoxanthin protects vascular endothelial function, promotes vasodilation and blood flow recovery, and aids in the recovery of myocardial function.
Yangsha Huangflavin also exhibits certain neuroprotective, antibacterial, and immunomodulatory activities, suggesting its broad potential for application in the treatment of various diseases.
Yangsha Huangxin exerts its pharmacological effects through multi-target and multi-pathway regulation, especially in diseases such as myocardial infarction, with targets including APP, PTPN1, MAOA, ABCB1, ABCG2, SYNJ2, ALOX5, TRPV1, CNR1, and SHBG.
In summary, mycetin demonstrates a complex yet effective mechanism of action by coordinating multiple targets to regulate cardiomyocyte metabolism, inflammation, apoptosis, and repair processes.
The druggability parameters of Yangsha Huangxin indicate that it has promising potential for drug development. Its molecular weight is 284.26, meeting the drug affinity requirements of the Lipinski rule. The LogP value was 3.04, indicating moderate lipid solubility, which is beneficial for cell membrane penetration and oral absorption. TPSA is 63.6 Ų, supporting good bioavailability and cell permeability.
In terms of safety, myoyer filavin is non-hepatotoxic and non-cardiotoxic, and does not inhibit hERG channels, reducing the risk of arrhythmias. A negative Ames test indicates no genotoxicity and relatively high safety. The low ability to penetrate the blood-brain barrier suggests that its potential side effects on the central nervous system are relatively small.
Pharmacokinetic studies show that yangbroxanthin is well absorbed orally but has certain limitations in bioavailability due to metabolic enzyme activity. Its main metabolic pathways include phase I and phase II metabolism in the liver, generating water-soluble metabolites that are excreted by the kidneys. Moderate half-life, suitable for daily administration. In the future, optimizing their pharmacokinetic properties through structural modification or drug carrier technologies will further enhance their clinical application value.
Based on the multi-target, multi-mechanism action characteristics and good safety profile of yang-sha-sha-xanthin, it has broad application prospects in the future in the prevention and treatment of cardiovascular diseases, especially myocardial infarction. Its antioxidant, anti-inflammatory, and cell-protective effects provide new ideas for intervention in myocardial ischemia-reperfusion injury. In addition, the antitumor and antidiarrheal activities of yangya shaxanthin also lay the foundation for its application in adjunctive tumor therapy and digestive system diseases.
Although clinical research on yangyaxiaofin is still in its early stages, with deeper elucidation of pharmacological mechanisms and optimization of druggability, its potential as a natural drug or drug-leading compound is becoming increasingly prominent. In the future, in vivo pharmacodynamics, toxicology, and pharmacokinetic systematic research should be strengthened, with preclinical and clinical trials conducted to clarify effective dosage, safety range, and indications.
Additionally, due to its multi-target properties, Yangsha Huangxin can be combined with other drugs to exert synergistic effects. The application of novel drug delivery systems, such as nanocarriers and liposomes, will also help improve their bioavailability and targeting, driving their clinical translation.
As a structurally unique monohydroxymonomethoxyflavone, yangsha flavonoids demonstrate significant potential as a new natural medicine due to their diverse pharmacological activities and good druggability. Its research progress in anti-tumor, antidiarrheal, and cardiovascular protection—especially in multi-target regulation related to myocardial infarction—provides a rich example for pharmacological research of natural products.
In the future, by deepening pharmacological research on yangya xiaofin, optimizing its pharmacokinetic properties, and conducting systematic clinical evaluations, it is expected to move from the laboratory to clinical application, becoming an effective natural medicine for treating various diseases. Research on Yangsha Huangxin not only enriches the pharmacological knowledge system of flavonoid compounds but also provides valuable resources and insights for the development of natural product drugs.
Shenshuai
Wenjing
Hedandan
